Deutsche Bank assumed coverage on shares of Humana (NYSE:HUM) in a report issued on Thursday morning, BenzingaRatingsTable reports. The brokerage issued a hold rating on the insurance provider’s stock.

A number of other research analysts also recently weighed in on the company. Morgan Stanley increased their target price on Humana from $315.00 to $342.00 and gave the company an overweight rating in a report on Friday, August 23rd. JPMorgan Chase & Co. increased their target price on Humana from $288.00 to $322.00 and gave the company an overweight rating in a report on Thursday, August 1st. Cantor Fitzgerald raised Humana from a neutral rating to an overweight rating and increased their target price for the company from $300.00 to $345.00 in a report on Monday, August 12th. Piper Jaffray Companies raised their price objective on Humana from $315.00 to $341.00 and gave the stock an overweight rating in a research note on Thursday, August 1st. Finally, SunTrust Banks raised their price objective on Humana to $340.00 and gave the stock a hold rating in a research note on Thursday, August 1st. Two research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $341.95.

Shares of NYSE:HUM opened at $274.69 on Thursday. The company has a market cap of $36.26 billion, a P/E ratio of 18.88, a PEG ratio of 1.16 and a beta of 0.84. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.75 and a quick ratio of 1.75. Humana has a 1 year low of $225.65 and a 1 year high of $355.88. The stock’s fifty day moving average price is $287.14 and its 200-day moving average price is $269.22.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.24 by $0.81. The firm had revenue of $16.25 billion for the quarter, compared to the consensus estimate of $15.88 billion. Humana had a return on equity of 22.47% and a net margin of 4.13%. The company’s quarterly revenue was up 13.9% on a year-over-year basis. During the same period in the prior year, the company posted $3.96 earnings per share. On average, sell-side analysts anticipate that Humana will post 17.67 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.80%. The ex-dividend date of this dividend is Friday, September 27th. Humana’s dividend payout ratio is currently 15.12%.

In related news, insider Brian P. Leclaire sold 7,239 shares of the stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the completion of the sale, the insider now owns 12,994 shares in the company, valued at $3,764,361.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.54% of the company’s stock.

Several large investors have recently added to or reduced their stakes in HUM. Cornerstone Advisors Inc. grew its holdings in Humana by 13.5% during the 2nd quarter. Cornerstone Advisors Inc. now owns 353 shares of the insurance provider’s stock valued at $94,000 after buying an additional 42 shares in the last quarter. Regentatlantic Capital LLC grew its holdings in Humana by 0.4% during the 2nd quarter. Regentatlantic Capital LLC now owns 9,617 shares of the insurance provider’s stock valued at $2,551,000 after buying an additional 42 shares in the last quarter. Cim Investment Mangement Inc. grew its holdings in Humana by 4.3% during the 2nd quarter. Cim Investment Mangement Inc. now owns 1,125 shares of the insurance provider’s stock valued at $298,000 after buying an additional 46 shares in the last quarter. Savant Capital LLC grew its holdings in Humana by 2.5% during the 2nd quarter. Savant Capital LLC now owns 1,968 shares of the insurance provider’s stock valued at $522,000 after buying an additional 48 shares in the last quarter. Finally, Greenleaf Trust grew its holdings in Humana by 3.4% during the 2nd quarter. Greenleaf Trust now owns 1,652 shares of the insurance provider’s stock valued at $438,000 after buying an additional 55 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Story: Understanding each part of a balance sheet

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.